We are live on ! Find out more
ICM

Invenomic Capital Management Portfolio holdings

AUM $2.18B
1-Year Est. Return 0.03%
This Fund
S&P 500
This Quarter Est. Return
-0.18%
1 Year Est. Return
+0.03%
3 Year Est. Return
-6.37%
5 Year Est. Return
-25.27%
10 Year Est. Return
AUM
$1.88B
AUM Growth
-$312M
Cap. Flow
-$314M
Cap. Flow %
-16.69%
Top 10 Hldgs %
23.69%
Holding
207
New
35
Increased
64
Reduced
46
Closed
62

Top Sells

Rank Stock Value
1
QDEL icon
QuidelOrtho
QDEL
+$37.1M
2
CMCSA icon
Comcast
CMCSA
+$36.9M
3
ILMN icon
Illumina
ILMN
+$32.3M
4
C icon
Citigroup
C
+$29.7M
5
VTRS icon
Viatris
VTRS
+$22.4M

Sector Composition

Rank Sector Weight
1 Technology 20.32%
2 Consumer Discretionary 17.17%
3 Energy 12.32%
4 Healthcare 9.35%
5 Consumer Staples 8.66%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
CPAY icon
201
Corpay
CPAY
$26.2B
-8,364
Closed -$2.36M
MAGN
202
Magnera Corp
MAGN
$466M
-30,635
Closed -$773K
B
203
DELISTED
Barnes Group Inc.
B
-237,777
Closed -$7.76M
TWKS
204
DELISTED
Thoughtworks Holding, Inc. Common Stock
TWKS
-130,557
Closed -$628K
EVBG
205
DELISTED
Everbridge, Inc. Common Stock
EVBG
-112,071
Closed -$2.72M
HRT
206
DELISTED
HireRight Holdings Corporation
HRT
-462,762
Closed -$6.22M

Similar funds

Invenomic Capital Management's Q1 2024 Portfolio in Review

As of Q1 2024, Invenomic Capital Management held 207 positions worth $1.88B, down 14% from $2.19B the previous quarter. Its ten largest holdings account for 24% of the portfolio.

Invenomic Capital Management withdrew a net $314M in Q1 2024, closing 62 positions and reducing 46 holdings. Its most notable exit was QuidelOrtho, an estimated $37.1M position sold in full.

By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 19% a quarter earlier, followed by Consumer Discretionary and Energy.

Against the trend, Invenomic Capital Management opened a new position in Archer Daniels Midland worth $37.9M.

  • Invenomic Capital Management's largest Q1 2024 buy was Archer Daniels Midland: 603,681 shares worth $37.9M.
  • Invenomic Capital Management added most to 3M in Q1 2024, an estimated $23.6M increase.
  • Invenomic Capital Management's biggest Q1 2024 reduction was Illumina, cutting an estimated $32.3M.
  • Invenomic Capital Management fully exited QuidelOrtho in Q1 2024, selling an estimated $37.1M.
  • Invenomic Capital Management's ten largest holdings make up 24% of its $1.88B portfolio in Q1 2024.
  • Invenomic Capital Management opened 35 new positions and closed 62 in Q1 2024.
  • Invenomic Capital Management's portfolio value fell 14% quarter-over-quarter to $1.88B.

Based on Invenomic Capital Management's 13F filing for Q1 2024, filed 15 May 2024.